GLP-1 Agonist Use in Multiple Sclerosis Patients: A Survey of Utilization Patterns
Background
Glucagon-like peptide-1 receptor agonists (GLP1RAs), such as semaglutide and tirzepatide, are increasingly prescribed for conditions like type 2 diabetes and obesity. Despite their growing use, there is limited understanding of the frequency and characteristics associated with GLP1RA use among individuals diagnosed with multiple sclerosis (MS).
Study Design
Results
Among the 4181 eligible participants, 7.4% reported having ever used GLP1RAs, while 5.5% were current users of these medications. Individuals who had ever used GLP1RAs were found to be significantly younger and exhibited a higher prevalence of cardiometabolic conditions (e.g., type 2 diabetes, obesity). > Strikingly, 37.3% of participants who had never used GLP1RAs still had a clear medical indication for their use, highlighting a substantial gap in treatment. This suggests that a significant proportion of MS patients who could potentially benefit from GLP1RAs for their comorbidities are not currently receiving them, despite appropriate medical grounds.
Why It Matters
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the importance of healthcare providers treating MS patients actively screening for and discussing GLP1RA use for appropriate indications. Further research, potentially including Phase II or human trials, is crucial to explore not only the cardiometabolic benefits but also any potential direct effects of GLP1RAs on MS progression or symptoms, given emerging interest in their neuroprotective properties.